Oct 22, 2024 | News, Press Release
Yibin Kang, PhD, chairs Scientific Advisory Board that includes experts in translational and early-phase clinical development activities Seattle, WA — October 22, 2024, Kayothera, Inc., a preclinical-stage therapeutics company developing first-in-class, oral, small... Oct 14, 2024 | News, Press Release
Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera’s evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA —... 
Apr 3, 2024 | Events, News
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at BioNJ BioPartnering on May 14th. Apr 3, 2024 | Events, News
Join our Co-Founder Dr. Mark Esposito as he shares an update on Kayothera at Life Science Innovation Northwest (LSINW) 2024 on April 18th at 11:05 AM – 12:15 PM. Sep 18, 2023 | News, Press Release
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...
